PNEUMOCOCCAL VACCINE (PNEUMOVAX, PREVNAR)

Course overview

Pneumococcal vaccine is U.S. FDA-approved to immunize adults ≥ 50 years, children 6 weeks–71 months, and at-risk patients of any age against Streptococcus pneumoniae infection; PCV13 is also indicated for prevention of S. pneumoniae-associated acute otitis media in children 6 weeks –71 months. This continuing education module is designed to give the reader/learner an increased understanding of pneumococcal vaccine, including its uses, mechanism of action, dosage and administration, drug interactions, contraindications, precautions, and adverse reactions. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.